Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Up 233.4% in May

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 14,745 shares, an increase of 233.4% from the May 14th total of 4,423 shares. Based on an average daily trading volume, of 6,576 shares, the short-interest ratio is currently 2.2 days. Approximately 0.0% of the shares of the company are sold short.

Bavarian Nordic Price Performance

Shares of BVNRY stock traded up $0.10 during trading hours on Friday, reaching $9.45. 6,412 shares of the company traded hands, compared to its average volume of 2,559. Bavarian Nordic has a 12-month low of $8.66 and a 12-month high of $13.00. The company has a market cap of $2.25 billion, a P/E ratio of 12.43 and a beta of 1.19. The firm has a 50-day moving average price of $9.89 and a 200 day moving average price of $9.93.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.The firm had revenue of $165.70 million for the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.